Pamidronate Disodium (Aredia®)

Common name: Pamidronate Disodium
Brand name: Aredia®
 

What is Pamidronate Disodium?

Pamidronate Disodium belongs to the bisphosphonate class of drugs that is used to treat osteoporosis (bone thinning). It works by reducing the breakdown of bone.


How is Pamidronate Disodium administered?

Pamidronate disodium is administered intravenously.
 

What are possible side effects of this treatment?

Everyone responds differently to treatments for bone metastases – some experience many side effects while others experience very few. Below are some side effects experienced by those who received pamidronate disodium. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Abdominal pain
  • Bone pain
  • Difficulty sleeping
  • Headache
  • Loss of appetite
  • Nausea / vomiting
  • Weakness
 

Is Pamidronate Disodium covered in my province or territory?

Pamidronate disodium is covered by provincial drug programs in:
  • Alberta
  • British Columbia
  • Manitoba
  • Northwest Territories
  • Nunavut
  • Ontario
  • Prince Edward Island
  • Quebec
  • Saskatchewan
  • Yukon
Pamidronate Disodium is not covered by provincial drug programs in:
  • New Brunswick
  • Newfoundland & Labrador
  • Nova Scotia
 

Last Reviewed: July 2017

Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More

Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More


Click here for news archive